Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
Anthony EG, Richard E, Lipkowitz MS, Kelley ST, Alcaraz JE, Shaffer RA, Bhatnagar V. Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study. Pharmacogenet Genomics. 2013 Aug; 23(8):442-4.
-
Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6109-14.
-
Yadav S, Hasan N, Marjot T, Khan MS, Prasad K, Bentley P, Sharma P. Detailed analysis of gene polymorphisms associated with ischemic stroke in South Asians. PLoS One. 2013; 8(3):e57305.
-
Nagy ZS, Ross JA, Rodriguez G, Balint BL, Szeles L, Nagy L, Kirken RA. Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells. PLoS One. 2013; 8(2):e57326.
-
Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012 Sep 21; 586(19):3410-4.
-
Ebalunode JO, Ouyang Z, Liang J, Zheng W. Novel approach to structure-based pharmacophore search using computational geometry and shape matching techniques. J Chem Inf Model. 2008 Apr; 48(4):889-901.
-
Anderson AJ, Nicholson JM, Bakare O, Butcher RJ, Wilson TL, Scott KR. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides. Bioorg Med Chem. 2006 Feb 15; 14(4):997-1006.
-
Singh SP, Barrett EG, Kalra R, Razani-Boroujerdi S, Langley RJ, Kurup V, Tesfaigzi Y, Sopori ML. Prenatal cigarette smoke decreases lung cAMP and increases airway hyperresponsiveness. Am J Respir Crit Care Med. 2003 Aug 01; 168(3):342-7.
-
Crocker IC, Ohia SE, Church MK, Townley RG. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol. 1998 Nov; 102(5):797-804.